Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.

Lai MT, Munshi V, Lu M, Feng M, Hrin-Solt R, McKenna PM, Hazuda DJ, Miller MD.

Viruses. 2016 Sep 23;8(10). pii: E263. doi: 10.3390/v8100263.


Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Lu M, Felock PJ, Munshi V, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Gomez R, Anthony NJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. doi: 10.1128/AAC.00102-12. Epub 2012 Mar 5.


Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD.

Antimicrob Agents Chemother. 2010 Nov;54(11):4812-24. doi: 10.1128/AAC.00829-10. Epub 2010 Aug 30.


Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

Wang YJ, McKenna PM, Hrin R, Felock P, Lu M, Jones KG, Coburn CA, Grobler JA, Hazuda DJ, Miller MD, Lai MT.

J Virol Methods. 2010 May;165(2):230-7. doi: 10.1016/j.jviromet.2010.02.002. Epub 2010 Feb 11.


Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2424-31. doi: 10.1128/AAC.01559-08. Epub 2009 Mar 16.


Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.

J Infect Dis. 2007 Apr 1;195(7):980-8. Epub 2007 Feb 20.


Immunogenicity of cytopathic and noncytopathic viral vectors.

Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC.

J Virol. 2006 Jul;80(13):6259-66.


Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ.

Virology. 2006 Jan 20;344(2):363-77. Epub 2005 Oct 14.


Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.

Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ.

Virology. 2005 Jan 5;331(1):82-93.


Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.

McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ.

J Virol. 2004 Dec;78(24):13455-9.


Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.

McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ.

Curr HIV Res. 2003 Apr;1(2):229-37. Review.


Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.

McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ.

J Virol. 2003 Jan;77(1):237-44.


HIV-1 vaccines: the search continues.

McGettigan JP, McKenna PM, Schnell MJ.

Clin Lab Med. 2002 Sep;22(3):799-820, viii. Review.


Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.

Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, Markham PD, Richardson E, Aldrich K, Arora K, Murty L, Carter L, Zolla-Pazner S, Sinangil F.

J Virol. 1998 Dec;72(12):10275-80.


Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1.

Geffin RB, Scott GB, Melenwick M, Hutto C, Lai S, Boots LJ, McKenna PM, Kessler JA 2nd, Conley AJ.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):579-90.


Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.

Boots LJ, McKenna PM, Arnold BA, Keller PM, Gorny MK, Zolla-Pazner S, Robinson JE, Conley AJ.

AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1549-59.


Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.

Kessler JA 2nd, McKenna PM, Emini EA, Chan CP, Patel MD, Gupta SK, Mark GE 3rd, Barbas CF 3rd, Burton DR, Conley AJ.

AIDS Res Hum Retroviruses. 1997 May 1;13(7):575-82.


The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate.

Conley AJ, Kessler JA 2nd, Boots LJ, McKenna PM, Schleif WA, Emini EA, Mark GE 3rd, Katinger H, Cobb EK, Lunceford SM, Rouse SR, Murthy KK.

J Virol. 1996 Oct;70(10):6751-8.


Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines.

Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM, Mellors JW.

Antimicrob Agents Chemother. 1994 Oct;38(10):2409-14.


In-home care of mildly ill children: risk management issues.

Nordhoff JA, McKenna PM.

Perspect Healthc Risk Manage. 1992 Spring;12(2):12-6. No abstract available.


An innovative approach: one hospital's experience with prisoners as patients.

McMahon S, McKenna PM.

Hosp Health Serv Adm. 1987 Feb;32(1):109-17.


Role negotiation: a strategy for facilitating an interprofessional health care team.

McKenna PM.

Nurs Leadersh. 1981 Dec;4(4):23-8. No abstract available.


Supplemental Content

Loading ...
Support Center